1. Фармакокинетика Мексидола у крыс

1. Фармакокинетика Мексидола у крыс после его внутрибрюшинного введения. Изучение фармакокинетики мексидола было проведено на 70 белых беспородных крысах-самцах с массой 160-180 гр. Водный раствор Мексидола вводили животным внутрибрюшинно в дозе 150 мг/кг. Установлено, что Мексидол у крыс всасывается из брюшной полости довольно быстро с периодом полуабсорбции 0,94 часа и определяется на протяжении 24 часов. Изучена биотрансформация Мексидола и выявлены 5 предварительных метаболитов, представленных деалкилированными и в основном конъюгированными продуктами превращения. Метаболит II (2,6-диметил-3-оксипиридин), наряду с неизмененным веществом, также обладает высокой фармакологической активностью. Выявленные корреляции между динамикой содержания Мексидола в плазме и мозге крыс, его анксиолитическим действием, а также изменениями электрофизиологических показателей, указывают на важную роль фармакокинетических закономерностей Мексидола в проявлении его различных видов фармакологической активности.

Результаты (английский) 1:

1. Pharmacokinetics in rats-Mexidola after his intraperitoneal injection. Study of pharmacokinetics of mexidol was held at 70 noninbred albino male rats weighing 160-180 Gr. Aqueous solution of Mexidol injected intraperitoneally to animals in a dose of 150 mg/kg. Found that rats Mexidol absorbed from the abdominal cavity rather quickly with a period of poluabsorbcii 0.94 hours and determined for 12:00 am. Biotransformation is studied and identified preliminary 5 Mexidola metabolites, dealkilirovannymi and presented in the main application kongugirovannami products. Metabolite II (2.6-dimethyl-3-oksipiridin), along with unchanged substance also has high pharmacological activity. Identified a correlation between dynamics of Mexidol content in plasma and brain of rats, his anxiolytic action, as well as changes of electrophysiological indices indicate the important role of the pharmacokinetic of Mexidol regularities of its various types of pharmacological activity.

Результаты (английский) 2:

1. Mexidol pharmacokinetics in rats after intraperitoneal administration. A study of the pharmacokinetics mexidol was conducted on 70 white mongrel male rats weighing 160-180 g. The aqueous solution Mexidol administered intraperitoneally in a dose of 150 mg / kg. It was found that rats Mexidol absorbed from the abdominal cavity rather quickly with a period of 0.94 hours and poluabsorbtsii determined over 24 hours. Biotransformation Mexidol studied and identified the five preliminary metabolites submitted dealkylated and mainly conjugated products of transformation. Metabolite II (2,6-dimethyl-3-hydroxypyridin), along with the unmodified substance also has high pharmacological activity. The correlation between the dynamics of content Mexidol in the plasma and brain of rats, its anxiolytic effects, as well as changes in the electrophysiological indicators point to an important role of pharmacokinetic Mexidol regularities in the manifestation of its various types of pharmacological activity.

Результаты (английский) 3:

1. Pharmacokinetics Мексидола in rats after his внутрибрюшинного introduction. The study pharmacokinetics мексидола was held 70white беспородных rats-самцах with earth 160-180 gr.Aqueous solution Мексидола imposed experiment raparative animals in the dose 150 mg/kg). It is established that Мексидол in rats is sucked from the abdomen rather quickly with the period полуабсорбции 0,94 Hours, and is for 24 hours. Studied биотрансформация Мексидола and identified 5 of the preliminary metabolites, submitted by деалкилированными and largely конъюгированными products making.Metabolite II (2.6 -диметил-3-оксипиридин), together with the unchanged substance, also has a high pharmacological activity. The correlation between the dynamics of Мексидола in plasma and brain in rats,His анксиолитическим action, as well as revised ep indicators,Indicate the important role agents administered (pharmacokinetics patterns Мексидола in manifestations of its various types of pharmacological activity.